Core Concepts
Topical ruxolitinib shows efficacy and safety in dermatological conditions.
Abstract
Standalone Note here
Abstract
Topical ruxolitinib developed as a local alternative to systemic JAK-inhibitors.
Studies show improvement in atopic dermatitis, vitiligo, psoriasis, and lichen planus.
Conflicting results in alopecia areata.
Favorable safety profile and tolerability compared to oral JAK-inhibitors.
Introduction
Immune-mediated skin conditions cause significant morbidity.
Recent advances target JAK-STAT pathway for treatment.
JAK-inhibitors developed for immune-mediated skin diseases.
Topical ruxolitinib approved for atopic dermatitis and vitiligo.
Summary
Topical ruxolitinib offers promising results in various dermatological conditions.
Stats
Topical 1.5% RUX cream FDA approved for AD in September 2021 and nonsegmental vitiligo in July 2022.
Quotes
"Topical ruxolitinib formulations show improvement in atopic dermatitis, vitiligo, psoriasis, and lichen planus."
"Favorable safety profile and higher tolerability of topical ruxolitinib compared to oral JAK-inhibitors."